R&D Institute, Enzychem Lifesciences, 107 Gwanggyo-ro, Suwon, South Korea.
Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Kwahak-ro, Daejeon, South Korea.
Sci Rep. 2024 Oct 8;14(1):23402. doi: 10.1038/s41598-024-73951-2.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease worldwide. However, it is still urgent to develop innovative treatments that can effectively manage refractory patients with unpredictable chronic disease courses. In this study, we evaluated the therapeutic efficacy of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) as a novel agent for AD treatment using a human-like mouse model of AD. PLAG significantly improved 2,4-dinitrochlorobenzene (DNCB)-induced AD skin lesions compared to those in mice treated with DNCB alone. PLAG substantially modulated the AD-induced infiltration of monocytes and eosinophils into skin lesions and humoral systemic responses involving immunoglobulin E (IgE), interleukin (IL)-4, and IL-13, restoring them to a normal state. Next, we compared the therapeutic efficacy of PLAG and abrocitinib for severe AD treatment. PLAG exhibited a significant therapeutic effect on AD skin lesions compared to abrocitinib. Unlike abrocitinib, PLAG significantly reduced AD-induced eosinophil infiltration to a level similar to that observed in untreated negative controls. Notably, both PLAG and abrocitinib downregulated IgE, IL-4, and IL-13 in a similar pattern, reaching levels similar to those in the untreated negative controls. Our findings strongly suggest that PLAG may serve as a therapeutic agent for AD with an efficacy comparable to that of abrocitinib.
特应性皮炎（AD）是全球最常见的慢性炎症性皮肤病。然而，仍然迫切需要开发创新的治疗方法，以有效管理不可预测的慢性疾病病程的难治性患者。在这项研究中，我们使用 AD 的类人小鼠模型评估了 1-棕榈酰-2-亚油酰-3-乙酰基-rac-甘油（PLAG）作为 AD 治疗的新型药物的治疗效果。与单独用 DNCB 治疗的小鼠相比，PLAG 显著改善了 2,4-二硝基氯苯（DNCB）诱导的 AD 皮肤损伤。PLAG 大量调节 AD 诱导的单核细胞和嗜酸性粒细胞浸润到皮肤病变和体液全身反应，涉及免疫球蛋白 E（IgE）、白细胞介素（IL）-4 和 IL-13，并将其恢复到正常状态。接下来，我们比较了 PLAG 和阿布罗替尼治疗严重 AD 的疗效。与阿布罗替尼相比，PLAG 对 AD 皮肤病变具有显著的治疗效果。与阿布罗替尼不同，PLAG 显著降低 AD 诱导的嗜酸性粒细胞浸润，使其水平与未治疗的阴性对照相似。值得注意的是，PLAG 和阿布罗替尼均以相似的方式下调 IgE、IL-4 和 IL-13，达到与未治疗的阴性对照相似的水平。我们的研究结果强烈表明，PLAG 可能是一种治疗 AD 的治疗药物，其疗效与阿布罗替尼相当。
